Literature DB >> 12824013

A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor Xa inhibitors.

Scott M Sheehan1, John J Masters, Michael R Wiley, Stephen C Young, John W Liebeschuetz, Stuart D Jones, Christopher W Murray, Jeffrey B Franciskovich, David B Engel, Wayne W Weber, Jothirajah Marimuthu, Jeffrey A Kyle, Jeffrey K Smallwood, Mark W Farmen, Gerald F Smith.   

Abstract

A novel isonitrile derivative was synthesized and used in an Ugi four component coupling reaction to explore aryl group substitution effects on inhibition of the coagulation cascade serine protease factor Xa.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824013     DOI: 10.1016/s0960-894x(03)00462-1

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

Review 1.  Chemistry and biology of multicomponent reactions.

Authors:  Alexander Dömling; Wei Wang; Kan Wang
Journal:  Chem Rev       Date:  2012-03-22       Impact factor: 60.622

2.  Construction of functionalized tricyclic dihydropyrazino-quinazolinedione chemotypes via an Ugi/N-acyliminium ion cyclization cascade.

Authors:  Steven Gunawan; Christopher Hulme
Journal:  Tetrahedron Lett       Date:  2013-08-14       Impact factor: 2.415

3.  Towards a facile and convenient synthesis of highly functionalized indole derivatives based on multi-component reactions.

Authors:  Constantinos G Neochoritis; Alexander Dömling
Journal:  Org Biomol Chem       Date:  2014-03-14       Impact factor: 3.876

4.  Hydrazine-mediated cyclization of Ugi products to synthesize novel 3-hydroxypyrazoles.

Authors:  Arthur Y Shaw; Jonathan A McLaren; Gary S Nichol; Christopher Hulme
Journal:  Tetrahedron Lett       Date:  2012-03-24       Impact factor: 2.415

5.  Ugi/Robinson-Gabriel reactions directed toward the synthesis of 2,4,5-trisubstituted oxazoles.

Authors:  Arthur Y Shaw; Zhigang Xu; Christopher Hulme
Journal:  Tetrahedron Lett       Date:  2012-02-13       Impact factor: 2.415

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.